Function and mutual interaction of BiP‐, PERK‐, and IRE1α‐dependent signalling pathways in vascular tumours. Issue 2 (12th May 2020)

• Record Type: Journal Article
• Authors: Anspach, Laura; Tsaryk, Roman; Seidmann, Larissa; Unger, Ronald E; Jayasinghe, Caren; Simiantonaki, Nektaria; Kirkpatrick, C James; Pröls, Felicitas
• Is Part Of: Journal of pathology. Volume 251:Issue 2(2020)
• Page Start: 123
• Page End: 134
• Publication Date: 2020-05-12
• Subjects: angiosarcoma -- haemangioma -- chaperone -- VEGFR2 -- unfolded protein response, crosstalk -- tumour angiogenesis; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.5423
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: Spontaneously regressing infantile haemangiomas and aggressive angiosarcomas are vascular tumours with excessive angiogenesis. When analysing haemangiomas and angiosarcomas immunohistochemically with respect to their chaperone profiles we found that angiosarcomas have significantly elevated protein levels of binding immunoglobulin protein (BIP) and PERK with concomitant attenuated IRE1α levels, whereas haemangioma tissue exhibits the same pattern as embryonal skin tissue. We show that BiP is essential for the maintenance of VEGFR2 protein, which is expressed in the endothelium of both tumour types. When studying the effects of BiP, the IRE1α/Xbp1 ‐, and PERK/ATF4‐signalling pathways on the migration and tube‐forming potential of endothelial cells, we show that downregulation of BiP, as well as inhibition of the kinase activity of IRE1α, inhibit in vitro angiogenesis. Downregulation of PERK (PKR‐like kinase; PKR = protein kinase R) levels promotes Xbp1 splicing in endoplasmic reticulum (ER)‐stressed cells, indicating that in angiosarcoma the elevated PERK levels might result in high levels of unspliced Xbp1, which have been reported to promote cell proliferation and increase tumour malignancy. The data presented in this study revealed that in addition to BiP or PERK, the kinase domains of IRE1α and Xbp1 could be potential targets for the development of novel therapeutic approaches for treating angiosarcomas and to control tumour angiogenesis. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.